The neuroprotective effect of lovastatin on MPP<sup>+</sup>-induced neurotoxicity is not mediated by PON2

Yoshajandith Aguirre-Vidal, Sergio Montes, Luis Tristan-López, Laura Anaya-Ramos, John Teiber, Camilo Ríos, Verónica Baron-Flores, Antonio Monroy-Noyola

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of the pigmented dopaminergic neurons in the substantia nigra pars compacta with subsequent striatal dopamine (DA) deficiency and increased lipid peroxidation. The etiology of the disease is still unclear and it is thought that PD may be caused by a combination of genetic and environmental factors. In the search of new pharmacological options, statins have been recognized for their potential application to treat PD, due to their antioxidant effect. The aim of this work is to contribute in the characterization of the neuroprotective effect of lovastatin in a model of PD induced by 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>). Male Wistar rats (200-250g) were randomly allocated into 4 groups and administered for 7 days with different pharmacological treatments. Lovastatin administration (5mg/kg) diminished 40% of the apomorphine-induced circling behavior, prevented the striatal DA depletion and lipid peroxides formation by MPP<sup>+</sup> intrastriatal injection, as compared to the group of animals treated only with MPP<sup>+</sup>. Lovastatin produced no change in paraoxonase-2 (PON2) activity. It is evident that lovastatin conferred neuroprotection against MPP<sup>+</sup>-induced protection but this effect was not associated with the induction of PON2 in the rat striatum.

Original languageEnglish (US)
Pages (from-to)166-170
Number of pages5
JournalNeuroToxicology
Volume48
DOIs
StatePublished - May 1 2015

Fingerprint

Aryldialkylphosphatase
Lovastatin
Neuroprotective Agents
Parkinson Disease
Corpus Striatum
Dopamine
Pharmacology
1-Methyl-4-phenylpyridinium
Rats
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Apomorphine
Lipid Peroxides
Dopaminergic Neurons
Neurodegenerative Diseases
Lipid Peroxidation
Wistar Rats
Antioxidants
Neurons
Animals
Injections

Keywords

  • Dopamine
  • Lipoperoxidation
  • Lovastatin
  • Paraoxonase-2
  • Parkinson

ASJC Scopus subject areas

  • Neuroscience(all)
  • Toxicology

Cite this

Aguirre-Vidal, Y., Montes, S., Tristan-López, L., Anaya-Ramos, L., Teiber, J., Ríos, C., ... Monroy-Noyola, A. (2015). The neuroprotective effect of lovastatin on MPP<sup>+</sup>-induced neurotoxicity is not mediated by PON2. NeuroToxicology, 48, 166-170. https://doi.org/10.1016/j.neuro.2015.03.012

The neuroprotective effect of lovastatin on MPP<sup>+</sup>-induced neurotoxicity is not mediated by PON2. / Aguirre-Vidal, Yoshajandith; Montes, Sergio; Tristan-López, Luis; Anaya-Ramos, Laura; Teiber, John; Ríos, Camilo; Baron-Flores, Verónica; Monroy-Noyola, Antonio.

In: NeuroToxicology, Vol. 48, 01.05.2015, p. 166-170.

Research output: Contribution to journalArticle

Aguirre-Vidal, Y, Montes, S, Tristan-López, L, Anaya-Ramos, L, Teiber, J, Ríos, C, Baron-Flores, V & Monroy-Noyola, A 2015, 'The neuroprotective effect of lovastatin on MPP<sup>+</sup>-induced neurotoxicity is not mediated by PON2', NeuroToxicology, vol. 48, pp. 166-170. https://doi.org/10.1016/j.neuro.2015.03.012
Aguirre-Vidal, Yoshajandith ; Montes, Sergio ; Tristan-López, Luis ; Anaya-Ramos, Laura ; Teiber, John ; Ríos, Camilo ; Baron-Flores, Verónica ; Monroy-Noyola, Antonio. / The neuroprotective effect of lovastatin on MPP<sup>+</sup>-induced neurotoxicity is not mediated by PON2. In: NeuroToxicology. 2015 ; Vol. 48. pp. 166-170.
@article{029d26c9154444518e53bcea6ad72325,
title = "The neuroprotective effect of lovastatin on MPP+-induced neurotoxicity is not mediated by PON2",
abstract = "Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of the pigmented dopaminergic neurons in the substantia nigra pars compacta with subsequent striatal dopamine (DA) deficiency and increased lipid peroxidation. The etiology of the disease is still unclear and it is thought that PD may be caused by a combination of genetic and environmental factors. In the search of new pharmacological options, statins have been recognized for their potential application to treat PD, due to their antioxidant effect. The aim of this work is to contribute in the characterization of the neuroprotective effect of lovastatin in a model of PD induced by 1-methyl-4-phenylpyridinium (MPP+). Male Wistar rats (200-250g) were randomly allocated into 4 groups and administered for 7 days with different pharmacological treatments. Lovastatin administration (5mg/kg) diminished 40{\%} of the apomorphine-induced circling behavior, prevented the striatal DA depletion and lipid peroxides formation by MPP+ intrastriatal injection, as compared to the group of animals treated only with MPP+. Lovastatin produced no change in paraoxonase-2 (PON2) activity. It is evident that lovastatin conferred neuroprotection against MPP+-induced protection but this effect was not associated with the induction of PON2 in the rat striatum.",
keywords = "Dopamine, Lipoperoxidation, Lovastatin, Paraoxonase-2, Parkinson",
author = "Yoshajandith Aguirre-Vidal and Sergio Montes and Luis Tristan-L{\'o}pez and Laura Anaya-Ramos and John Teiber and Camilo R{\'i}os and Ver{\'o}nica Baron-Flores and Antonio Monroy-Noyola",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.neuro.2015.03.012",
language = "English (US)",
volume = "48",
pages = "166--170",
journal = "NeuroToxicology",
issn = "0161-813X",
publisher = "Elsevier",

}

TY - JOUR

T1 - The neuroprotective effect of lovastatin on MPP+-induced neurotoxicity is not mediated by PON2

AU - Aguirre-Vidal, Yoshajandith

AU - Montes, Sergio

AU - Tristan-López, Luis

AU - Anaya-Ramos, Laura

AU - Teiber, John

AU - Ríos, Camilo

AU - Baron-Flores, Verónica

AU - Monroy-Noyola, Antonio

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of the pigmented dopaminergic neurons in the substantia nigra pars compacta with subsequent striatal dopamine (DA) deficiency and increased lipid peroxidation. The etiology of the disease is still unclear and it is thought that PD may be caused by a combination of genetic and environmental factors. In the search of new pharmacological options, statins have been recognized for their potential application to treat PD, due to their antioxidant effect. The aim of this work is to contribute in the characterization of the neuroprotective effect of lovastatin in a model of PD induced by 1-methyl-4-phenylpyridinium (MPP+). Male Wistar rats (200-250g) were randomly allocated into 4 groups and administered for 7 days with different pharmacological treatments. Lovastatin administration (5mg/kg) diminished 40% of the apomorphine-induced circling behavior, prevented the striatal DA depletion and lipid peroxides formation by MPP+ intrastriatal injection, as compared to the group of animals treated only with MPP+. Lovastatin produced no change in paraoxonase-2 (PON2) activity. It is evident that lovastatin conferred neuroprotection against MPP+-induced protection but this effect was not associated with the induction of PON2 in the rat striatum.

AB - Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of the pigmented dopaminergic neurons in the substantia nigra pars compacta with subsequent striatal dopamine (DA) deficiency and increased lipid peroxidation. The etiology of the disease is still unclear and it is thought that PD may be caused by a combination of genetic and environmental factors. In the search of new pharmacological options, statins have been recognized for their potential application to treat PD, due to their antioxidant effect. The aim of this work is to contribute in the characterization of the neuroprotective effect of lovastatin in a model of PD induced by 1-methyl-4-phenylpyridinium (MPP+). Male Wistar rats (200-250g) were randomly allocated into 4 groups and administered for 7 days with different pharmacological treatments. Lovastatin administration (5mg/kg) diminished 40% of the apomorphine-induced circling behavior, prevented the striatal DA depletion and lipid peroxides formation by MPP+ intrastriatal injection, as compared to the group of animals treated only with MPP+. Lovastatin produced no change in paraoxonase-2 (PON2) activity. It is evident that lovastatin conferred neuroprotection against MPP+-induced protection but this effect was not associated with the induction of PON2 in the rat striatum.

KW - Dopamine

KW - Lipoperoxidation

KW - Lovastatin

KW - Paraoxonase-2

KW - Parkinson

UR - http://www.scopus.com/inward/record.url?scp=84928718579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928718579&partnerID=8YFLogxK

U2 - 10.1016/j.neuro.2015.03.012

DO - 10.1016/j.neuro.2015.03.012

M3 - Article

C2 - 25842176

AN - SCOPUS:84928718579

VL - 48

SP - 166

EP - 170

JO - NeuroToxicology

JF - NeuroToxicology

SN - 0161-813X

ER -